Catalase watches ClinicalTrials.gov for the quiet edits that move biotech stocks — a status flip, a moved endpoint, a shortened timeline — and turns them into a plain-language alert before the market catches up.
By the time a change is visible on a headline, it's already priced in. By the time it hits a registry page, it doesn't have to be.
// hash-gated scanning, not guessworkCatalase runs the same pipeline on every ticker you track, every day the registry updates.
Add the biotech tickers you care about. Catalase instantly tracks all active Phase 2/3 trials linked to them.
Our continuous system watches registry records 24/7 for subtle updates to timelines, status, and trial parameters.
Noise and minor admin updates are automatically filtered out so you only get alerted when a meaningful shift occurs.
Receive a concise, plain-English summary instantly on your preferred channel before the news hits major headlines.
A real, publicly logged status change on a Pfizer trial record — the kind of edit that's easy to miss and expensive to miss.
$PFE Shift: Trial reopened enrollment (Active→Recruiting). Impact: Signals renewed confidence in protocol, near-term catalyst risk rises.
Catalase isn't trying to cover every biotech in existence or tell you what to trade. It's narrow, fast, and quiet until something real happens.
Administrative updates and formatting edits are automatically filtered out. You only receive notifications for material changes that impact trial timelines or outcomes.
No endpoint jargon, no raw registry text. Every alert is one sentence: what changed, and why it matters to the stock.
From registry update to notification, the whole pipeline is built to finish before most traders have refreshed the page twice.
Send alerts to SMS, Telegram, or Discord — wherever you're actually going to see them first.
Catalase translates registry data. It never tells you what to buy or sell — the decision, and the judgment, stay yours.
Every alert attempt is logged with its destination and outcome, so nothing gets silently dropped or duplicated.
Three tiers, all built on the same detection pipeline. No tier gets a diluted version of the signal — only more of it.
No. Catalase provides market intelligence, not financial advice. It monitors official trial registries and translates complex technical updates into clear, understandable summaries. You retain full control over your trading decisions.
Catalase evaluates incoming updates to confirm they represent significant shifts in status, endpoints, or completion dates. Minor cosmetic edits are discarded so you are never spammed with noise.
Alerts are processed instantly when a change is detected on the public registry and delivered directly to your chosen channel within minutes.
Any public company with active Phase 2 or Phase 3 trials registered on ClinicalTrials.gov. You simply select the specific tickers you want to monitor.
Early access rolls out to mid-cap and small-cap oncology and neurology names first.
Catalase provides informational alerts only and does not constitute investment advice.